These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 34854206)

  • 21. The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1.
    Yi M; Zhang J; Li A; Niu M; Yan Y; Jiao Y; Luo S; Zhou P; Wu K
    J Hematol Oncol; 2021 Feb; 14(1):27. PubMed ID: 33593403
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bintrafusp Alfa: A Bifunctional Fusion Protein Targeting PD-L1 and TGF-β, in Patients with Pretreated Colorectal Cancer: Results from a Phase I Trial.
    Spira A; Wertheim MS; Kim EJ; Tan B; Lenz HJ; Nikolinakos P; Rich PL; Jehl G; Machl A; Ito R; Gulley JL; Kopetz S
    Oncologist; 2023 Feb; 28(2):e124-e127. PubMed ID: 36576431
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β.
    Lan Y; Zhang D; Xu C; Hance KW; Marelli B; Qi J; Yu H; Qin G; Sircar A; Hernández VM; Jenkins MH; Fontana RE; Deshpande A; Locke G; Sabzevari H; Radvanyi L; Lo KM
    Sci Transl Med; 2018 Jan; 10(424):. PubMed ID: 29343622
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-TGF-β/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer.
    Yi M; Wu Y; Niu M; Zhu S; Zhang J; Yan Y; Zhou P; Dai Z; Wu K
    J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36460337
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synergistic efficacy of simultaneous anti-TGF-β/VEGF bispecific antibody and PD-1 blockade in cancer therapy.
    Niu M; Yi M; Wu Y; Lyu L; He Q; Yang R; Zeng L; Shi J; Zhang J; Zhou P; Zhang T; Mei Q; Chu Q; Wu K
    J Hematol Oncol; 2023 Aug; 16(1):94. PubMed ID: 37573354
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies.
    Strauss J; Gatti-Mays ME; Cho BC; Hill A; Salas S; McClay E; Redman JM; Sater HA; Donahue RN; Jochems C; Lamping E; Burmeister A; Marté JL; Cordes LM; Bilusic M; Karzai F; Ojalvo LS; Jehl G; Rolfe PA; Hinrichs CS; Madan RA; Schlom J; Gulley JL
    J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33323462
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dual PD-L1 and TGF-b blockade in patients with recurrent respiratory papillomatosis.
    Robbins Y; Friedman J; Clavijo PE; Sievers C; Bai K; Donahue RN; Schlom J; Sinkoe A; Hinrichs CS; Allen C; Abdul Sater H; Gulley JL; Norberg S
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34462327
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transforming growth factor-β signalling in tumour resistance to the anti-PD-(L)1 therapy: Updated.
    Mortezaee K; Majidpoor J
    J Cell Mol Med; 2023 Feb; 27(3):311-321. PubMed ID: 36625080
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine.
    Smalley Rumfield C; Pellom ST; Morillon Ii YM; Schlom J; Jochems C
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554612
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors.
    Yi M; Niu M; Wu Y; Ge H; Jiao D; Zhu S; Zhang J; Yan Y; Zhou P; Chu Q; Wu K
    J Hematol Oncol; 2022 Oct; 15(1):142. PubMed ID: 36209176
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cancer stem cells in immunoregulation and bypassing anti-checkpoint therapy.
    Rouzbahani E; Majidpoor J; Najafi S; Mortezaee K
    Biomed Pharmacother; 2022 Dec; 156():113906. PubMed ID: 36306594
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Selection of the Recommended Phase 2 Dose for Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1.
    Vugmeyster Y; Wilkins J; Koenig A; El Bawab S; Dussault I; Ojalvo LS; De Banerjee S; Klopp-Schulze L; Khandelwal A
    Clin Pharmacol Ther; 2020 Sep; 108(3):566-574. PubMed ID: 31955412
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-PD-L1/TGF-βR fusion protein (SHR-1701) overcomes disrupted lymphocyte recovery-induced resistance to PD-1/PD-L1 inhibitors in lung cancer.
    Cheng B; Ding K; Chen P; Ji J; Luo T; Guo X; Qiu W; Ma C; Meng X; Wang J; Yu J; Liu Y
    Cancer Commun (Lond); 2022 Jan; 42(1):17-36. PubMed ID: 34981670
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined Inhibition of TGF-β Signaling and the PD-L1 Immune Checkpoint Is Differentially Effective in Tumor Models.
    Sow HS; Ren J; Camps M; Ossendorp F; Ten Dijke P
    Cells; 2019 Apr; 8(4):. PubMed ID: 30959852
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Patients with Esophageal Squamous Cell Carcinoma: Results from a Phase 1 Cohort in Asia.
    Lin CC; Doi T; Muro K; Hou MM; Esaki T; Hara H; Chung HC; Helwig C; Dussault I; Osada M; Kondo S
    Target Oncol; 2021 Jul; 16(4):447-459. PubMed ID: 33840050
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity.
    Chen SH; Dominik PK; Stanfield J; Ding S; Yang W; Kurd N; Llewellyn R; Heyen J; Wang C; Melton Z; Van Blarcom T; Lindquist KC; Chaparro-Riggers J; Salek-Ardakani S
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599020
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination of T cell-redirecting strategies with a bispecific antibody blocking TGF-β and PD-L1 enhances antitumor responses.
    Tapia-Galisteo A; Sánchez-Rodríguez I; Narbona J; Iglesias-Hernández P; Aragón-García S; Jiménez-Reinoso A; Compte M; Khan S; Tsuda T; Chames P; Lacadena J; Álvarez-Vallina L; Sanz L
    Oncoimmunology; 2024; 13(1):2338558. PubMed ID: 38623463
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Next-generation immunotherapy for solid tumors: combination immunotherapy with crosstalk blockade of TGFβ and PD-1/PD-L1.
    Quach HT; Hou Z; Bellis RY; Saini JK; Amador-Molina A; Adusumilli PS; Xiong Y
    Expert Opin Investig Drugs; 2022 Nov; 31(11):1187-1202. PubMed ID: 36448335
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Simultaneous targeting of TGF-β/PD-L1 synergizes with radiotherapy by reprogramming the tumor microenvironment to overcome immune evasion.
    Lan Y; Moustafa M; Knoll M; Xu C; Furkel J; Lazorchak A; Yeung TL; Hasheminasab SM; Jenkins MH; Meister S; Yu H; Schlegel J; Marelli B; Tang Z; Qin G; Klein C; Qi J; Zhou C; Locke G; Krunic D; Derner MG; Schwager C; Fontana RE; Kriegsmann K; Jiang F; Rein K; Kriegsmann M; Debus J; Lo KM; Abdollahi A
    Cancer Cell; 2021 Oct; 39(10):1388-1403.e10. PubMed ID: 34506739
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and Tolerability of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Asian Patients with Pretreated Recurrent or Refractory Gastric Cancer.
    Kang YK; Bang YJ; Kondo S; Chung HC; Muro K; Dussault I; Helwig C; Osada M; Doi T
    Clin Cancer Res; 2020 Jul; 26(13):3202-3210. PubMed ID: 32299818
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.